Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 po… Read more
Moleculin Biotech Inc (MBRX) - Net Assets
Latest net assets as of September 2025: $-26.92 Million USD
Based on the latest financial reports, Moleculin Biotech Inc (MBRX) has net assets worth $-26.92 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($20.35 Million) and total liabilities ($47.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-26.92 Million |
| % of Total Assets | -132.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | -66.58% |
| 10-Year Change | N/A |
| Growth Volatility | 123.46 |
Moleculin Biotech Inc - Net Assets Trend (2015–2024)
This chart illustrates how Moleculin Biotech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Moleculin Biotech Inc (2015–2024)
The table below shows the annual net assets of Moleculin Biotech Inc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $5.98 Million | -77.07% |
| 2023-12-31 | $26.07 Million | -50.04% |
| 2022-12-31 | $52.19 Million | -33.93% |
| 2021-12-31 | $78.99 Million | +341.57% |
| 2020-12-31 | $17.89 Million | +14.89% |
| 2019-12-31 | $15.57 Million | +9.10% |
| 2018-12-31 | $14.27 Million | -16.63% |
| 2017-12-31 | $17.12 Million | +14.42% |
| 2016-12-31 | $14.96 Million | +2108.91% |
| 2015-12-31 | $-744.70K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Moleculin Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15261864000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.05% |
| Other Comprehensive Income | $-41.00K | -0.69% |
| Other Components | $159.38 Million | 2665.73% |
| Total Equity | $5.98 Million | 100.00% |
Moleculin Biotech Inc Competitors by Market Cap
The table below lists competitors of Moleculin Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Full Wang International Development Co Ltd
TWO:6219
|
$22.47 Million |
|
Powercom Co Ltd
TW:3043
|
$22.47 Million |
|
Danakali Ltd
PINK:SBMSF
|
$22.48 Million |
|
Drb Industrial
KO:163560
|
$22.49 Million |
|
GREAT ELM GROUP NEW-001
F:PNC
|
$22.46 Million |
|
Optiscan Imaging Ltd
AU:OIL
|
$22.46 Million |
|
HBR Realty Empreendimentos Imobiliários S.A
SA:HBRE3
|
$22.45 Million |
|
Defence Therapeutics Inc
OTCQB:DTCFF
|
$22.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Moleculin Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 26,073,000 to 5,979,000, a change of -20,094,000 (-77.1%).
- Net loss of 21,763,000 reduced equity.
- New share issuances of 4,660,000 increased equity.
- Other comprehensive income decreased equity by 32,000.
- Other factors decreased equity by 2,959,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.76 Million | -363.99% |
| Share Issuances | $4.66 Million | +77.94% |
| Other Comprehensive Income | $-32.00K | -0.54% |
| Other Changes | $-2.96 Million | -49.49% |
| Total Change | $- | -77.07% |
Book Value vs Market Value Analysis
This analysis compares Moleculin Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-294.35 | $2.16 | x |
| 2016-12-31 | $3424.99 | $2.16 | x |
| 2017-12-31 | $2074.15 | $2.16 | x |
| 2018-12-31 | $1239.64 | $2.16 | x |
| 2019-12-31 | $860.37 | $2.16 | x |
| 2020-12-31 | $681.36 | $2.16 | x |
| 2021-12-31 | $1102.19 | $2.16 | x |
| 2022-12-31 | $684.22 | $2.16 | x |
| 2023-12-31 | $329.94 | $2.16 | x |
| 2024-12-31 | $43.41 | $2.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Moleculin Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -363.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.83x
- Recent ROE (-363.99%) is below the historical average (-90.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-673.89K |
| 2016 | -26.25% | 0.00% | 0.00x | 1.10x | $-5.42 Million |
| 2017 | -57.28% | -108944.44% | 0.00x | 1.14x | $-11.52 Million |
| 2018 | -83.21% | 0.00% | 0.00x | 1.37x | $-13.30 Million |
| 2019 | -84.81% | 0.00% | 0.00x | 1.62x | $-14.76 Million |
| 2020 | -97.01% | 0.00% | 0.00x | 1.63x | $-19.14 Million |
| 2021 | -20.12% | 0.00% | 0.00x | 1.06x | $-23.79 Million |
| 2022 | -55.61% | 0.00% | 0.00x | 1.10x | $-34.24 Million |
| 2023 | -114.18% | 0.00% | 0.00x | 1.47x | $-32.38 Million |
| 2024 | -363.99% | 0.00% | 0.00x | 2.83x | $-22.36 Million |
Industry Comparison
This section compares Moleculin Biotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Moleculin Biotech Inc (MBRX) | $-26.92 Million | 0.00% | N/A | $22.47 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |